Anand R Rose1, Peter G Catcheside1, R Doug McEvoy1, Denzil Paul1, Dilip Kapur2, Emily Peak1, Andrew Vakulin3, Nicholas A Antic1. 1. Adelaide Institute for Sleep Health, Repatriation General Hospital, Daw Park, South Australia, Australia; ; Department of Medicine, Flinders University, Bedford Park, South Australia, Australia; 2. Pain Management Unit, Flinders Medical Centre, Bedford Park, South Australia, Australia; 3. Adelaide Institute for Sleep Health, Repatriation General Hospital, Daw Park, South Australia, Australia; ; Department of Medicine, Flinders University, Bedford Park, South Australia, Australia; ; Sleep and Circadian Research Group and NHMRC Centre for Integrated Research and Understanding of Sleep (CIRUS), Woolcock Institute of Medical Research, Central Clinical School, University of Sydney, Sydney, Australia.
Abstract
STUDY OBJECTIVES: The use of opioid medication for chronic pain has been increasing. The main aim of this study was to assess how many patients on opioids for chronic pain had sleep disordered breathing (SDB) and the type of SDB. The impact of these medications on daytime arterial blood gas (ABG) measurements and psychomotor vigilance was also studied. METHODS: Twenty-four patients (aged 18-75 years) on long-term opioids were prospectively recruited. Patients underwent home polysomnogram (PSG), psychomotor vigilance testing (PVT), and awake daytime ABG. Overnight PSG findings were compared to those of patients matched for age, sex, and BMI referred to our sleep service for evaluation of SDB. PVT results in the patient cohort were compared to PVT in healthy controls. RESULTS: Forty-six percent of opioid patients had severe SDB as defined by an apnea hypopnea index (AHI) > 30/h. The severity of SDB was similar in opioid-treated pain clinic patients and sleep clinic patients (mean ± SD AHI: Opioid-treated patients 32.7 ± 25.6; Sleep Study comparator group 28.9 ± 24.6, p = 0.6). Opioid patients had a higher frequency of central apneas and a lower arousal index (CAI: 3.9 ± 8.3 vs. 0.3 ± 0.5 events/h; p = 0.004, AI 8.0 ± 4.1 vs. 20.1 ± 13.8, p < 0.001). Pain clinic patients had impaired gas exchange during sleep and wakefulness. Nine of 20 (45%) had daytime hypercapnia, indicating a surprising number were in chronic respiratory failure. Morphine equivalent doses correlated with the severity of SDB. PVT was impaired when compared to a healthy PVT comparator group (RT: Opioid-treated patients 0.43 ± 0.27: Healthy PVT comparator group 0.28 ± 0.03 sec; p < 0.001). CONCLUSIONS: Patients on long-term opioids frequently have severe SDB, which in part is central in origin. PVT was markedly impaired. Half of the patients studied have evidence of chronic ventilatory failure. COMMENTARY: A commentary on this article appears in this issue on page 853
STUDY OBJECTIVES: The use of opioid medication for chronic pain has been increasing. The main aim of this study was to assess how many patients on opioids for chronic pain had sleep disordered breathing (SDB) and the type of SDB. The impact of these medications on daytime arterial blood gas (ABG) measurements and psychomotor vigilance was also studied. METHODS: Twenty-four patients (aged 18-75 years) on long-term opioids were prospectively recruited. Patients underwent home polysomnogram (PSG), psychomotor vigilance testing (PVT), and awake daytime ABG. Overnight PSG findings were compared to those of patients matched for age, sex, and BMI referred to our sleep service for evaluation of SDB. PVT results in the patient cohort were compared to PVT in healthy controls. RESULTS: Forty-six percent of opioid patients had severe SDB as defined by an apnea hypopnea index (AHI) > 30/h. The severity of SDB was similar in opioid-treated pain clinic patients and sleep clinic patients (mean ± SD AHI: Opioid-treated patients 32.7 ± 25.6; Sleep Study comparator group 28.9 ± 24.6, p = 0.6). Opioid patients had a higher frequency of central apneas and a lower arousal index (CAI: 3.9 ± 8.3 vs. 0.3 ± 0.5 events/h; p = 0.004, AI 8.0 ± 4.1 vs. 20.1 ± 13.8, p < 0.001). Pain clinic patients had impaired gas exchange during sleep and wakefulness. Nine of 20 (45%) had daytime hypercapnia, indicating a surprising number were in chronic respiratory failure. Morphine equivalent doses correlated with the severity of SDB. PVT was impaired when compared to a healthy PVT comparator group (RT: Opioid-treated patients 0.43 ± 0.27: Healthy PVT comparator group 0.28 ± 0.03 sec; p < 0.001). CONCLUSIONS:Patients on long-term opioids frequently have severe SDB, which in part is central in origin. PVT was markedly impaired. Half of the patients studied have evidence of chronic ventilatory failure. COMMENTARY: A commentary on this article appears in this issue on page 853
Authors: Gilles J Lavigne; Alberto Herrero Babiloni; Pierre Mayer; Raoul Daoust; Marc O Martel Journal: J Clin Sleep Med Date: 2020-02-13 Impact factor: 4.062
Authors: Talha Mubashir; Mahesh Nagappa; Nilufar Esfahanian; Joseph Botros; Abdul A Arif; Colin Suen; Jean Wong; Clodagh M Ryan; Frances Chung Journal: J Clin Sleep Med Date: 2020-06-15 Impact factor: 4.062
Authors: Ilene M Rosen; R Nisha Aurora; Douglas B Kirsch; Kelly A Carden; Raman K Malhotra; Kannan Ramar; Fariha Abbasi-Feinberg; David A Kristo; Jennifer L Martin; Eric J Olson; Carol L Rosen; James A Rowley; Anita V Shelgikar Journal: J Clin Sleep Med Date: 2019-11-15 Impact factor: 4.062
Authors: Sebastiano Mercadante; Claudio Adile; Patrizia Ferrera; Francesco Masedu; Marco Valenti; Federica Aielli Journal: Support Care Cancer Date: 2016-12-13 Impact factor: 3.603